Repligen Corp. Stock
Price
Target price
€123.55
€123.55
-2.110%
-2.65
-2.110%
€156.77
07.11.25 / Tradegate
WKN: 870980 / Symbol: RGEN / Name: Repligen Corp / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Repligen Corp. Stock
We can see a decrease in the price for Repligen Corp.. Compared to yesterday it has lost -€2.650 (-2.110%).
With 18 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 156 € there is a positive potential of 26.26% for Repligen Corp. compared to the current price of 123.55 €.
So far the community has only identified positive things for Repligen Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Repligen Corp. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Repligen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Repligen Corp. | -2.110% | -4.521% | -1.357% | -7.280% | -11.718% | -30.512% | -27.452% |
| Opko Health Inc. | -4.410% | 1.428% | -10.643% | -12.108% | -18.157% | -35.868% | -64.380% |
| Amicus Therapeutics Inc. | 1.940% | 0.000% | 14.493% | -23.301% | -13.661% | -21.205% | -55.367% |
| Hutchison China Meditech Ltd | 0.000% | 5.000% | -0.787% | -21.739% | -2.326% | 30.570% | -52.091% |
Comments
Repligen (NASDAQ:RGEN) had its price target raised by analysts at Evercore ISI from $155.00 to $175.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (NASDAQ:RGEN) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (NASDAQ:RGEN) was given a new $150.00 price target on by analysts at HSBC Holdings plc. They now have a "buy" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat